Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.
Original title: “J&J earnings set ‘negative tone’; Shkreli vs. the FTC”
Obesity-focused Zealand Pharma is buying into Generate:Biomedicines’s generative AI platform to create new multispecific drug candidates.
Original title: “Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs”
The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglutide in the Asian country.
Original title: “Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’”
Topline results from Phase 1b clinical trial in patients with Olmsted syndrome anticipated around year-end 2026 · NESS ZIONA, Israel, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Orvida Pharma, a clinical-stage biotechnology company developing first- and best-in-class treatments for rare and severe genetic skin diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted KM-023 (ontivatrep), the Company’s lead oral investigational therapy ... Topline results from Phase 1b clinical trial in patients with Olmsted syndrome anticipated around year-end 2026 · NESS ZIONA, Israel, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Orvida Pharma, a clinical-stage biotechnology company developing first- and best-in-class treatments for rare and severe genetic skin diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted KM-023 (ontivatrep), the Company’s lead oral investigational therapy for Olmsted syndrome, into the FDA’s Rare Disease Evidence Principles (RDEP) process. FDA’s Rare Disease Evidence Principles (RDEP) process aims to provide greater speed and predictability in the review of therapies for rare diseases with... Orvida’s management team comprises industry leaders with deep expertise in drug discovery, dermatological pharmaceutical development, and rare disease therapeutics. ... Investors and Media Marcy Nanus Managing Partner Trilon Advisors, LLC [email protected] GlobeNewswire · September 15, 2026 07:30 ET | Source: Orvida Pharma Ltd · Orvida Pharma Announces Interim Financing Led by Recordati to Advance Ontivatrep Development for Rare Genetic Skin Diseases · Proceeds to support continued clinical development of ontivatrep, an oral TRPV3 inhibitor, with Phase 1b topline results in Olmsted syndrome expected by the end of 2026 NESS ZIONA, Israel, Sept. There are currently no approved therapies for Olmsted syndrome. In April 2026, Orvida reported favorable Phase 1a safety data for ontivatrep from a randomized, placebo-controlled study in 30 healthy volunteers. The Company is currently conducting a Phase 1b clinical trial in patients with Olmsted syndrome in Europe and the United States.
Original title: “Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome”
Partnership expands Bespak’s intranasal dry powder capabilities
Original title: “Bespak and SNBL agree global access deal for FDA‑approved nasal device”
New long‑term results reinforce efficacy across AD and PN
Original title: “NEMLUVIO data show sustained three‑year responses in atopic dermatitis”
While Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects.
Original title: “Alnylam bulls and bears fight it out after business-shaking guidance cut”
While industry leaders are unsure whether the U.S. or China will prevail, they are largely united in the belief that Europe is lagging behind.
Original title: “European biotech leaders split on US-China fight for deal dominance, survey finds”
The first-time CEO says her own sponsors took chances on her—and that industry leaders need to do the same to rebuild momentum for gender equity.
Original title: “Jazz CEO calls on industry to help rebuild momentum for leadership diversity”